CD47 and CD40 — Drug Target

1 drugs 1 in Phase 3

All drugs that target CD47 and CD40 — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Bispecific antibody

Phase 3 pipeline (1)

CHS-1420 · Coherus Oncology, Inc. · Bispecific antibody · Oncology
CHS-1420 is a bispecific antibody that simultaneously engages CD47 on tumor cells and CD40 on antigen-presenting cells to enhance anti-tumor immunity.